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Abstract
Background. The aim of this pilot study was to evaluate intranasal buserelin for
luteal phase support and compare its efficacy with standard vaginal progesterone
in IVF/ICSI antagonist cycles. Methods. This is a prospective, randomized, open,
parallel group study. Forty patients underwent ovarian hyperstimulation with
human menopausal gonadotropin under pituitary inhibition with gonadotropin-
releasing hormone antagonist, while ovulation trigger and luteal support were
achieved using intranasal GnRH agonist (group A). Twenty patients had their
cycle downregulated with buserelin and stimulated with hMG, while ovulation
trigger was achieved using 10,000 IU human chorionic gonadotropin with luteal
support by intravaginal progesterone (group B). Results. No difference was
observed in estradiol levels. Progesterone levels on day 5 were significantly
lower in group A. However, significantly higher levels of luteinizing hormone were
observed in group A during the entire luteal phase. Pregn...
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Background. The aim of this pilot study was to evaluate intranasal buserelin for luteal phase support and compare its efficacy with
standard vaginal progesterone in IVF/ICSI antagonist cycles. Methods. This is a prospective, randomized, open, parallel group
study. Forty patients underwent ovarian hyperstimulation with human menopausal gonadotropin under pituitary inhibition with
gonadotropin-releasing hormone antagonist, while ovulation trigger and luteal support were achieved using intranasal GnRH
agonist (group A). Twenty patients had their cycle downregulated with buserelin and stimulated with hMG, while ovulation trigger
was achieved using 10,000 IUhuman chorionic gonadotropinwith luteal support by intravaginal progesterone (groupB).Results. No
difference was observed in estradiol levels. Progesterone levels on day 5 were significantly lower in group A. However, significantly
higher levels of luteinizing hormone were observed in group A during the entire luteal phase. Pregnancy rates (31.4% versus 22.2%),
implantation rates (22% versus 15.4%), and clinical pregnancy rates (25.7% versus 16.7%) were not statistically different between
groups, although a trend towards higher rates was observed in group A. No luteal phase lasting less than 10 days was recorded in
either group.Conclusion. Intranasal administration of buserelin is effective for providing luteal phase support in IVF/ICSI antagonist
protocols.
1. Introduction
Cycles resulting from controlled ovarian hyperstimulation
(COH), when downregulated with gonadotropin-releasing
hormone (GnRH) agonist or GnRH antagonist, commonly
result in luteal phase deficiency [1, 2]. This phenomenon is
characterized by low progesterone levels, delayed endome-
trial secretory transformation, and a shortened luteal phase of
less than ten days [3], resulting in reduced embryo implanta-
tion, lower pregnancy rates, and increased miscarriage rates.
For this reason, luteal phase support is a common practice in
IVF treatments, as it significantly improves embryo implan-
tation, pregnancy, and delivery rates [2].
Vaginal progesterone with or without estradiol and
intramuscular human chorionic gonadotropin (hCG) are
the current regimens used for luteal phase support. Since
hCG administration is associated with the risk of ovarian
hyperstimulation syndrome (OHSS), progesterone is the
preferred choice [4].
It was reported that GnRH agonists administered during
the luteal phase in addition to standard luteal phase support
improved pregnancy rates in IVF-stimulated cycles [5–14],
but the mechanism of this apparently beneficial effect is
poorly understood. GnRH agonists may support the corpus
luteum by stimulating the secretion of luteinizing hormone
(LH) by pituitary gonadotroph cells, by acting directly on the
endometrium through locally expressed receptors, or by their
direct effect on the embryo [6, 7].
The question as to whether GnRH agonist alone is able to
efficiently support the luteal phase nevertheless remains.
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Drop-out = 2
1: poor response
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No transfer = 3
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2: absence of fertilization
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Figure 1: Randomization and allocation of patients to the two groups. In group A, ovulation was triggered with buserelin and the luteal phase
was also supported by buserelin. In group B, ovulation was triggered with hCG and the luteal phase was supported with vaginal micronized
progesterone.
We previously reported that, in patients undergoing
COH, intranasal (IN) administration of buserelin for 15 days
is able to trigger final follicular maturation and has a marked,
dose-related effect on the luteal phase [15]. This observation
led to the conclusion that the optimal dose of buserelin for
luteal support in an antagonist protocol is 100 𝜇g 3 times per
day.
To further analyze the potential benefits of this new
protocol, our study objective was to assess the efficacy of
luteal phase GnRH agonist administration in cycles where
ovulationwas triggered byGnRHagonist and compare it with
a standard protocol using hCG to trigger ovulation, followed
by intravaginal progesterone as luteal support. To the best of
our knowledge, this is the first randomized controlled trial
using GnRH agonist as the only luteal phase support.
2. Materials and Methods
2.1. Study Design and Patient Randomization. In order to
study the effect of IN administration of GnRH agonist to trig-
ger and support the luteal phase, we initiated a single-center,
prospective, randomized, open, parallel group study. We
were looking to compare this method in patients undergoing
IVF/ICSI after stimulation of multiple follicular development
with human menopausal gonadotropin (hMG). Inclusion
criteria were the age between 18 and 39 and BMI ≥ 18 but
≤35, while exclusion criteria were a history of poor response,
systemic disease (diabetes, severe migraine, hepatic, renal, or
cardiovascular disease, and corticodependent asthma), and
ovarian cysts ≥11mm.
Computer-generated randomization was applied (2/1;
group A/B). Treatment allocation instructions were placed
in individually sealed envelopes to be opened at the center
in chronological order on the day of signing the informed
consent form.
In study group A, GnRH agonist (buserelin) was admin-
istered IN to trigger final follicular maturation and support
the luteal phase. In control group B, hCG was administered
to trigger final follicularmaturation and vaginal progesterone
to support the luteal phase.
The primary end-point was the comparison of pregnancy
rates between the two groups.
The study protocol and informed consent form were
approved by the institution’s ethics committee.
2.2. Ovarian Stimulation Protocol and Treatment Groups.
Sixty patients with infertility factors indicating IVF or ICSI
were enrolled in this study, as shown in Figure 1.
In study group A, 40 patients underwent COH using
hMG (Menopur, Ferring, Brussels, Belgium) at a dose rang-
ing from 150 to 450 IU daily. When the leading follicle
reached a mean diameter of 14mm, daily administration
of 0.25mg GnRH antagonist (Orgalutran; MSD, Brussels,
Belgium) was initiated every evening up to the day before
ovulation trigger.
When patients met the criteria for ovulation trigger (at
least 3 follicles >17mm), they received 200 𝜇g of IN buserelin
(Suprefact; Aventis, Brussels, Belgium), followed by 100 𝜇g
IN buserelin three times a day for luteal support starting the
next day, as previously published by our team [15]. This was
continued for a maximum of 16 days until the day of the
pregnancy test, whether or not it proved positive.
In control group B, 20 patients had a cycle downregulated
with GnRH agonist and stimulated with hMG at a dose
ranging from 150 to 450 IU daily. When they met the
criteria for ovulation trigger (at least 3 follicles >17mm),
they were given 10,000 IU subcutaneous hCG (Pregnyl;MSD,
Brussels, Belgium), followed by 200mg vaginal progesterone
three times a day (Utrogestan; Goodlife pharma, Lelystad,
Netherlands), starting on the day of oocyte pick-up for luteal
support. Progesterone was administered up to day 16 (day
of the pregnancy test). If the pregnancy test proved positive,
progesterone administration was continued up to week 12 of
pregnancy, which is a common practice in our center.
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Table 1: Patient demographics and stimulation parameters (mean ± SD).
Group A
(buserelin 3x/day)
𝑛 = 35
Group B
(micronized progesterone 3x/day)
𝑛 = 18
𝑃
Age (years) 32 ± 4.4 33 ± 4.5 NS
Range 2 ± 1.1 2 ± 1.3 NS
HMG (IU) 2526 ± 988 2614 ± 1077 NS
Day of trigger (=D0) 12.7 ± 2.7 12.9 ± 2.6 NS
Estradiol D0 (pg/mL) 2960 ± 1068 2929 ± 1439 NS
Progesterone D0 (ng/mL) 0.9 ± 0.4 1 ± 0.4 NS
Endometrial thickness D0 (mm) 9.8 ± 2.1 9.0 ± 3.0 NS
Pregnancy was diagnosed by measuring serum hCG
levels on day 14 of the luteal phase (day of first hCG/buserelin
administration = D0). A pregnancy test was considered
positive if an increase in serum hCGwas observed after a first
test showing at least >10mIU/mL. The implantation rate was
calculated as the number of gestational sacs divided by the
number of transferred embryos.
Clinical pregnancy was defined as the presence of an
intrauterine gestational sac with a positive heartbeat visual-
ized by vaginal ultrasound.
The duration of the luteal phase was calculated from day
1 (the first day after ovulation trigger) up to the day before
menstruation commenced.
IVF laboratory culture conditions were the same as those
previously described [15].
All embryos were transferred on day 3.
2.3. Hormone Assays. Serum estradiol, serum progesterone,
and serum LH concentrations were monitored on D0 (day of
ovulation trigger), D2, D5, D9, andD14. Hormone levels were
determined with commercially available kits routinely used
in our accredited clinical center’s central laboratory. Estra-
diol, progesterone, and LH were assayed using the Elecsys
2010 system (Roche Diagnostics GmbH, 68298 Mannheim,
Germany). The E2 intra-assay coefficient of variation (CV)
was <6% and the interassay CV was <6%; the P4 intra-
assay CV was <3% and the interassay CV was <6%; the LH
intra-assay CV was <2% and the interassay CV was <5%.
Serum hCG was assayed using the Beckman-Coulter system
(Anablis, Namur, Belgium), yielding an intra-assay CV of
<2% for a value <5mIU/mL and an interassay CV of <12%.
2.4. Statistical Analysis. Descriptive quantitative statistics
(mean and SD) were calculated for demographic and ovarian
stimulation status parameters, IVF/ICSI and embryo transfer
parameters, and luteal phase duration. Comparison between
groups was done using the student 𝑡-test. 𝑃 < 0.05 was
considered statistically significant.
3. Results
Sixty patients were randomized at a ratio of 2/1 (group
A/group B). Five patients dropped out of group A and
two from group B, leaving 53 patients eligible for analysis.
Patient groups did not differ in their basic demographic
characteristics, and COH parameters were also comparable
(Table 1).
The mean number of retrieved oocytes, cleaved embryos,
and transferred embryos did not show any statistical dif-
ference. Embryo transfer was performed in both groups,
with a mean number of 1.4 embryos per transfer (Table 2).
Furthermore, the mean number of good quality embryos was
similar in both groups.
In group A, 11 positive pregnancy tests were recorded
during the study. Nine pregnancies were confirmed as clinical
pregnancies, 7 of which were singleton and 2 were twin
pregnancies. One pregnancy ended in miscarriage at 9 weeks
and one was terminated because of spina bifida and another
for severe preeclampsia. Eight healthy babies were born after
37 weeks of pregnancy.
In group B, 4 positive pregnancy tests were recorded
during the study. Three pregnancies were confirmed as
clinical pregnancies, 2 of which were singleton and one was a
twin pregnancy. Four healthy babies were born after 37 weeks
of pregnancy.
While similar numbers of retrieved oocytes and trans-
ferred embryoswere found between groups, patients in group
A showed a tendency towards a higher pregnancy rate (31.4%
versus 22.2%), implantation rate (22% versus 15.4%), and
clinical pregnancy rate (25.7% versus 16.7%), despite the fact
there is no statistically significant difference (Table 2).
Endometrial thickness on D9 of the luteal phase was also
similar in both groups (10.7 ± 3mm versus 10.5 ± 4.4mm).
Hormone levels during the luteal phase are shown in
Figure 2. The progesterone profile during the luteal phase
was similar in both groups, except on D5, where it was
significantly higher (𝑃 < 0.05) in group B (91.4 ± 38.8 ng/mL)
than in group A (61.7 ± 36.9 ng/mL) (Figure 2(a)). Estra-
diol levels were comparable during the entire luteal phase
(Figure 2(b)). By contrast, mean serum LH levels were sig-
nificantly higher throughout the luteal phase in group A than
in group B (where serum LH levels were below the limit of
detection (<0.1 IU/L) in most samples taken between D2 and
D9) (Figure 2(c)).
The duration of the luteal phase assessed in patients who
did not become pregnant ranged between 11 and 21 days in
groupA (mean 13.8± 2.3) and between 11 and 19 days in group
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Table 2: IVF/ICSI cycle outcomes (mean ± SD).
Group A
(buserelin 3x/day)
𝑛 = 35
Group B
(micronized progesterone 3x/day)
𝑛 = 18
𝑃
Retrieved oocytes (𝑛) 10.1 ± 4.1 10.7 ± 5.9 NS
Cleaved embryos (𝑛) 5.8 ± 2.7 6.0 ± 3.2 NS
Transferred embryos (𝑛) 1.4 ± 0.5 1.4 ± 0.5 NS
Pregnancy rate/transfer 11/3531.4%
4/18
22.2% NS
Clinical pregnancy rate 9/3525.7%
3/18
16.7% NS
Implantation rate 11/5022%
4/26
15.4% NS
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Figure 2: Hormone levels during the luteal phase on D0 (day of ovulation trigger), D2, D5, D9, and D14. (a) Mean progesterone levels. (b)
Mean estradiol levels. (c) Mean LH levels.
B (mean 14.7 ± 2.7). No luteal phase lasting less than 10 days
was recorded in either group.
Buserelin treatment was well tolerated by all patients.
There was no further drop-out, and no significant adverse
events were reported in terms of local or systemic tolerance.
No OHSS requiring hospitalization was recorded.
4. Discussion
During the menstrual cycle, a normal luteal phase is required
for embryo implantation and evolution of pregnancy. The
luteal phase is the result of intermittent stimulation of the
corpus luteum by pituitary LH. During the luteal phase,
pituitary LH pulses are of low frequency, leading to extended
episodes of progesterone secretion at a rate of 3–5 per 24
hours [20]. Luteal phase deficiency is a common feature of
cycles resulting from COH [21] including GnRH antagonist-
treated cycles [22–24]. It is characterized by premature
regression of the corpus luteum, leading to a shortened
luteal phase (<10 days), low serum progesterone levels, and
delayed secretory transformation of the endometrium [25].
Consequences of luteal phase deficiency are reduced embryo
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implantation rates, lower pregnancy rates, and increased
miscarriage rates when pregnancy is established [2]. Besides
standard luteal phase support with progesterone, various
other methods have also been studied, including use of
low-dose hCG [26–30], hCG according to ovarian response
to stimulation [31], recombinant LH [32], and intensive
progesterone and estradiol administration [33–35]. Because
inadvertent administration of GnRH agonist does not appear
to compromise pregnancy outcome [36], a number of studies
have also investigated the potential benefits of using GnRH
agonist for luteal phase support in IVF/ICSI cycles (Tables 3
and 4). The findings are somewhat contradictory, however,
with studies identifying a positive [5, 7, 9, 10, 13], absent
[12, 14, 16], or negative [17, 19] impact on outcome in
long agonist stimulation protocols. Although the number of
studies investigating antagonist protocols is smaller, a similar
positive influence on implantation and pregnancy rates has
been reported in most of these [7, 11, 13, 15]. Protocols of
GnRH agonist administration vary, with intermittent single,
double, or multiple doses or continuous administration
during the luteal phase. It is noteworthy that all studies
use GnRH agonist in combination with other luteal phase
support methods previously mentioned. No comparison can
therefore be made between our results and those in the
reported literature. In our previous dose-finding study on the
use of GnRH agonist for luteal support, we demonstrated
that buserelin is able to induce final follicular maturation,
trigger ovulation, and support alone the luteal phase when
administered at the appropriate dose [15].
Luteal phase support after COH is even more important
when triggering with GnRH agonists. Previous randomized
controlled trials [37, 38] found that the use of GnRH agonist
to trigger ovulation was associated with negative clinical
results, namely, low implantation and clinical pregnancy rates
and high rates of early pregnancy loss, presumably related
to luteal phase insufficiency despite standard supplementa-
tion with progesterone and estradiol [27]. Only intensive
progesterone and estradiol support [33–35] and hCG [26–
31] or recombinant LH [32] were able to normalize the
luteal phase after GnRH agonist administration for ovulation
trigger. Finally, in a very recent Cochrane review, Youssef et
al. [39] reported that, in women undergoing fresh autologous
IVF/ICSI cycles, GnRH agonists were associated with a lower
ongoing pregnancy rate than that obtained with hCG (OR =
0.70; 95%CI: 0.54 to 0.91). However, the effect was dependent
on the type of luteal support provided.The higher pregnancy
rate in the hCG trigger group applied only to the GnRH
agonist trigger group that received luteal support without LH
activity (OR = 0.36, 95% CI: 0.21 to 0.62) [39].
Studies showing that implantation rates remain normal
in oocyte recipients and frozen-thawed cycles with embryos
issuing from protocols with GnRH agonist trigger [40, 41]
confirm that a deficient luteal phase is the main problem
leading to reduced outcomes.
In our study, similar outcome parameters were obtained
when GnRH agonist was used to trigger ovulation, demon-
strating that GnRH agonist (IN buserelin) is able to ade-
quately support the luteal phase. Indeed, the implantation
potential of our embryos did not appear to be hampered
compared to the standard protocol using hCG for ovulation
trigger and vaginal progesterone as luteal support. Further-
more, an additional study conducted in our department, in
which hCG was used to trigger ovulation and GnRH agonist
(without any other supplementation) to support the luteal
phase, found similar pregnancy rates (data not shown) and
hence corroborates the current study.
The beneficial effect of GnRH agonist during the luteal
phase may be linked to its impact on the embryo or a
direct or indirect effect on the endometrium. Indeed, GnRH
receptors have been shown to be present in preimplantation
human embryos in the luteal phase at both the mRNA and
protein levels [42, 43], and different observations support the
hypothesis that GnRH agonist exerts a direct beneficial effect
on embryos [6, 7]. Animal experiments suggest that GnRH
agonists can enhance the in vitro development of embryos
[42, 44–46]. In addition, GnRH agonists appear to have a
regulatory impact on the synthesis and secretion of hCG by
preimplanted embryos and the placenta [7, 47, 48].
Direct action on uterine tissue may also be responsible
for the effects of GnRH agonists in the luteal phase. The
presence of a GnRH receptor showing a dynamic pattern
(more intense in the luteal phase) was demonstrated in
human endometrium, both in the epithelium and stroma,
providing evidence that GnRH may play a key role as
a molecular autocrine-paracrine regulator in embryonic-
endometrial interactions during early implantation [49–51].
The corpus luteum is another possible GnRH agonist
target, though it is questionable whether such action would
occur through the secretion of pituitary hormones or by
direct action in the ovary [52]. In cycles with GnRH antag-
onists, it is speculated that the stimulation of corpus luteum
activity by GnRH agonist may result from the stimulation of
LH secretion, given that, despite the blockade, the pituitary
gland remains responsive to GnRH or GnRH agonist [11].
In our study, we found completely different LH profiles
during the luteal phase between the two groups, with sig-
nificantly higher LH levels when GnRH agonist was admin-
istered for luteal support. Although preliminary, our data
suggest that maintaining LH secretion throughout the luteal
phase by repeated administration of GnRH agonist could
overcome the drawbacks of GnRH agonist-induced final
follicular maturation followed by standard luteal support.
Besides LH-mediated stimulation of steroid production
by the corpus luteum, LH activity could also have an impact
on the endometrium through LH receptors expressed in
the endometrium [53–55] or by promoting expression and
secretion of relaxin [56], angiogenic and growth factors, and
cytokines involved in implantation [57].
In conclusion, our study confirms that GnRH agonist
is able to trigger ovulation and support the luteal phase
in antagonist IVF cycles, showing comparable efficacy to
the standard protocol. Furthermore, this new approach has
several advantages over other forms of luteal support in terms
of convenience for the patient, because nasal administration
is easily done anywhere, is not painful, and does not require
the help of a nurse. Since GnRH agonist was the only drug
administered for luteal support, compared to other proto-
cols that add GnRH agonist to their classic luteal support,
6 International Journal of Endocrinology
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this new protocol can contribute to more patient-friendly
ART.
However, although all babies born in this study were
in good health, our data need to be corroborated by larger
series, and caution should still be exercised concerning the
condition and state of health of children issuing from this
protocol.
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